Benedict A - Search Results

1

Overview of parametric survival analysis for health-economic applications.

Ishak KJ, Kreif N, Benedict A, Muszbek N. Ishak KJ, et al. Among authors: benedict a. Pharmacoeconomics. 2013 Aug;31(8):663-75. doi: 10.1007/s40273-013-0064-3. Pharmacoeconomics. 2013. PMID: 23673905 Review.

2

Modelling survival in hepatocellular carcinoma.

Muszbek N, Kreif N, Valderrama A, Benedict A, Ishak J, Ross P. Muszbek N, et al. Among authors: benedict a. Curr Med Res Opin. 2012 Jul;28(7):1141-53. doi: 10.1185/03007995.2012.691422. Epub 2012 Jun 26. Curr Med Res Opin. 2012. PMID: 22563794

3

Simulation and matching-based approaches for indirect comparison of treatments.

Ishak KJ, Proskorovsky I, Benedict A. Ishak KJ, et al. Among authors: benedict a. Pharmacoeconomics. 2015 Jun;33(6):537-49. doi: 10.1007/s40273-015-0271-1. Pharmacoeconomics. 2015. PMID: 25795232

4

Assessment-Schedule Matching in Unanchored Indirect Treatment Comparisons of Progression-Free Survival in Cancer Studies.

Kapetanakis V, Prawitz T, Schlichting M, Ishak KJ, Phatak H, Kearney M, Stevens JW, Benedict A, Bharmal M. Kapetanakis V, et al. Among authors: benedict a. Pharmacoeconomics. 2019 Dec;37(12):1537-1551. doi: 10.1007/s40273-019-00831-3. Pharmacoeconomics. 2019. PMID: 31555968 Free article.

5

The economic consequences of noncompliance in cardiovascular disease and related conditions: a literature review.

Muszbek N, Brixner D, Benedict A, Keskinaslan A, Khan ZM. Muszbek N, et al. Among authors: benedict a. Int J Clin Pract. 2008 Feb;62(2):338-51. doi: 10.1111/j.1742-1241.2007.01683.x. Int J Clin Pract. 2008. PMID: 18199282 Free PMC article. Review.

6

An economic evaluation of docetaxel and paclitaxel regimens in metastatic breast cancer in the UK.

Benedict A, Cameron DA, Corson H, Jones SE. Benedict A, et al. Pharmacoeconomics. 2009;27(10):847-59. doi: 10.2165/10899510-000000000-00000. Pharmacoeconomics. 2009. PMID: 19803539

7

Cost-effectiveness analysis of anastrozole versus tamoxifen in adjuvant therapy for early-stage breast cancer - a health-economic analysis based on the 100-month analysis of the ATAC trial and the German health system.

Lux MP, Wöckel A, Benedict A, Buchholz S, Kreif N, Harbeck N, Kreienberg R, Kaufmann M, Beckmann MW, Jonat W, Hadji P, Distler W, Raab G, Tesch H, Weyers G, Possinger K, Schneeweiss A. Lux MP, et al. Among authors: benedict a. Onkologie. 2010;33(4):155-66. doi: 10.1159/000286233. Epub 2010 Mar 19. Onkologie. 2010. PMID: 20389141 Clinical Trial.

8

The Life and Death of the End of Life Treatment Appraisal Criteria in Nice Technology Appraisals?

Kiss Z, Muszbek N, Benedict A. Kiss Z, et al. Among authors: benedict a. Value Health. 2014 Nov;17(7):A661. doi: 10.1016/j.jval.2014.08.2427. Epub 2014 Oct 26. Value Health. 2014. PMID: 27202408 Free article. No abstract available.

9

The cost effectiveness of rufinamide in the treatment of Lennox-Gastaut syndrome in the UK.

Benedict A, Verdian L, Maclaine G. Benedict A, et al. Pharmacoeconomics. 2010;28(3):185-99. doi: 10.2165/11313640-000000000-00000. Pharmacoeconomics. 2010. PMID: 20151724

10

Quality of life and drug costs associated with switching antipsychotic medication to once-daily extended release quetiapine fumarate in patients with schizophrenia.

Järbrink K, Kreif N, Benedict A, Locklear J. Järbrink K, et al. Among authors: benedict a. Curr Med Res Opin. 2009 Mar;25(3):709-16. doi: 10.1185/03007990902738810. Curr Med Res Opin. 2009. PMID: 19196221

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

189 results

Search Page

Filters